References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327–36
- Andersson K-E. Pharmacological treatment of urinary incontinence. In: Incontinence, 2nd international consultation of incontinence Plymouth: Plymbridge Distributors Ltd; 2002. p. 479–511
- Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001;19:299–306
- Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3 receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001;21: 243–8
- Andersson K-E. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol 2002;1:23–8
- Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease specific guidelines for patients with multiple conditions. New Engl J Med 2004;351:2870–4
- Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002;60:50–5
- Andersson K-E, Kahler K, Ebinger U. Prevalence of cardiovascular co-morbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract]. https://www icsofficeorg/publications/2007/PDF/0342 PDF [last accessed 7 June 2007]
- Andersson K-E, Kahler K, Ebinger U. Heart rates in OAB patients prior to initiation of treatment with antimuscarinics [abstract]. https://www.icsoffice.org/publications/2007/PDF/0437.PDF [last accessed 7 June 2007]
- Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Br Med J 2006;332:455–9
- Nitti VW. Clinical impact of overactive bladder. Rev Urol 2002;4:S2–S6
- Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005;48:471–7
- Chapple CR. Darifenacin is effective in improving the major symptoms of overactive bladder: a pooled analysis of phase III studies [abstract]. Eur Urol Suppl 2004;3:130
- Hill S, Elhilali M, Millard R, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. [in press]
- DuBeau CE. The aging lower urinary tract. J Urol 2006;175:S11–S15
- Dmochowski RR, Sanders SW, Appell RA, et al. Bladder-health diaries: an assessment of 3-day vs 7-day entries. Br J Urol Int 2005;96:1049–54
- Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. Br J Urol Int 2005;95:580–6
- Noether G. Sample size determination for some common nonparametric tests. J Am Stat Assoc 1987;82:645–7
- Desu MM, Raghavarao D. Nonparametric statistical methods for complete and censored data. Boca Raton: Chapman and Hall/CRC; 2003
- Malone-Lee JG, Walsh JB, Maugourd M-F, et al. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700–5
- Zorzitto ML, Holliday PJ, Jewett MAS, et al. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 1989;18:195–200
- Szonyi G, Collas Dm, Ding YY et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995;24:287–91
- van Leeuwen JH, Castro R, Busse M, et al. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006;50:440–52
- DuBeau CE, Khullar V, Versi E. ‘Unblinding’ in randomized controlled drug trials for urinary incontinence: implications for assessing outcomes when adverse effects are evident. Neurourol Urodyn 2005;24:13–20
- Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563–74
- Coyne K, Matza LS. Validation of the perception of bladder condition measure in overactive bladder [abstract]. http://www.icsoffice.org/publications/2002/pdf/231.pdf [last accessed 19 June 2007]